Author:
Chen Yan,Xie Jianfeng,Wu Wenjuan,Li Shusheng,Hu Yu,Hu Ming,Li Jinxiu,Yang Yi,Huang Tingrong,Zheng Kun,Wang Yishan,Kang Hanyujie,Huang Yingzi,Jiang Li,Zhang Wei,Zhong Ming,Sang Ling,Zheng Xia,Pan Chun,Zheng Ruiqiang,Li Xuyan,Tong Zhaohui,Qiu Haibo,Weng Li,Du Bin
Abstract
BackgroundThe benefits of intravenous immunoglobulin administration are controversial for critically ill COVID-19 patients.MethodsWe analyzed retrospectively the effects of immunoglobulin administration for critically ill COVID-19 patients. The primary outcome was 28-day mortality. Inverse probability of treatment weighting (IPTW) with propensity score was used to account for baseline confounders. Cluster analysis was used to perform phenotype analysis.ResultsBetween January 1 and February 29, 2020, 754 patients with complete data from 19 hospitals were enrolled. Death at 28 days occurred for 408 (54.1%) patients. There were 392 (52.0%) patients who received intravenous immunoglobulin, at 11 (interquartile range (IQR) 8, 16) days after illness onset; 30% of these patients received intravenous immunoglobulin prior to intensive care unit (ICU) admission. By unadjusted analysis, no difference was observed for 28-day mortality between the immunoglobulin and non-immunoglobulin groups. Similar results were found by propensity score matching (n = 506) and by IPTW analysis (n = 731). Also, IPTW analysis did not reveal any significant difference between hyperinflammation and hypoinflammation phenotypes.ConclusionNo significant association was observed for use of intravenous immunoglobulin and decreased mortality of severe COVID-19 patients. Phenotype analysis did not show any survival benefit for patients who received immunoglobulin therapy.
Funder
Ministry of Science and Technology of the People's Republic of China
Subject
Immunology,Immunology and Allergy